Deucravacitinib Plus Topical C/BD Effective in Moderate to Severe Psoriasis: Analysis
Key Takeaways
New reseearch shows C/BD foam improved outcomes in of deucravacitinib recipients with chronic plaque psoriasis.
Skin and quality-of-life improvements reported at week 12 were carried through week 24.
There were no serious or treatment-limiting adverse events in the study population.
New research in the Journal of Drugs in Dermatology suggests that adding topical calcipotriene/betamethasone dipropionate (C/BD) foam to oral deucravacitinib therapy improves outcomes and quality of life in patients with moderate to severe chronic plaque psoriasis.
The research team conducted a prospective study of 30 adults with psoriasis (mean age, 45.4 years; 63% male) and assigned all participants to receive deucravacitinib 6 mg daily. At 8 weeks, those achieving PASI 75 (n = 5) continued monotherapy, while those with PASI 25–74 (n = 20) added once-daily C/BD foam for 4 weeks. Patients with PASI <25 (n = 3) were discontinued.
According to the results, mean improvement from baseline to week 12 was 83% for PASI, 52% for PGA, 78% for BSA, and 74% for DLQI in patients requiring topical add-on. All gains continued through week 24. The combo therapy was well tolerated and no serious adverse events or discontinuations were reported.
Source: Bagel J, et al. Journal of Drugs in Dermatology. 2025;24(8):744.